Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you do not take any medications that are contraindicated (not recommended) with d-cycloserine or any medications that may affect cognition, such as sedatives, hypnotics, narcotics, and opiates. If you are on such medications, you may need to stop them to participate.
What data supports the effectiveness of this treatment?
Is computerized cognitive training safe for humans?
How is Cognitive Training different from other treatments for cognitive disorders?
Cognitive Training is unique because it uses computer-based exercises to improve cognitive function, making it an ideal tool for enhancing attention and reaction times. Unlike traditional therapies, it can be tailored and integrated into a broader therapeutic framework, providing a flexible and engaging way to achieve necessary therapeutic intensity.1791011
What is the purpose of this trial?
This trial is testing whether a medication called d-cycloserine, combined with a computer program to improve memory and attention, can help people with chronic tinnitus. The medication may enhance the brain's ability to learn and adapt, which could reduce tinnitus symptoms and improve memory and focus. Participants will receive either the medication or a similar treatment along with the computer program. D-cycloserine is being studied to see if it can help with learning and memory for tinnitus treatment.
Research Team
Jay F Piccirillo, MD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cognitive training with either d-cycloserine or placebo for 5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cognitive Training
- D-cycloserine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor